GHR and breast cancer: The chemotherapy-sensitizing effects of direct GHR antagonism in preclinical models of human melanoma, breast cancer, and liver cancer exhibit a consistent suppression of ABC multidrug transporters and markers of EMT, leading us to hypothesize that targeting GHR in PDAC can reverse the chemoresistant phenotype of this cancer.